Evidence map›Paper›PMID 38510811›Full record

ArticleFrontiers in chemistry2024

Anti-leishmanial activity of

Kelly Cristina Oliveira de Albuquerque, Andreza do Socorro Silva da Veiga, Fernando Tobias Silveira, Marliane Batista Campos, Ana Paula Lima da Costa, Ananda Karolyne Martins Brito, Paulo Ricardo de Souza Melo, Sandro Percario, Fábio Alberto de Molfetta, Maria Fâni Dolabela

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. ACS omega · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kelly Cristina Oliveira de AlbuquerqueBiotechnology and Biodiversity Postgraduate Program (BIONORTE), Federal University of Pará, Belém, PA, Brazil.
Andreza do Socorro Silva da VeigaPharmaceutical Innovation Postgraduate Program, Federal University of Pará, Belém, PA, Brazil.
Fernando Tobias SilveiraLeishmaniasis Laboratory, Evandro Chagas Institute, Ananindeua, PA, Brazil.
Marliane Batista CamposLeishmaniasis Laboratory, Evandro Chagas Institute, Ananindeua, PA, Brazil.
Ana Paula Lima da CostaLaboratory of Molecular Modeling, Institute of Exact and Natural Sciences, Federal University of Pará, Belém, PA, Brazil.
Ananda Karolyne Martins BritoFaculty of Pharmacy, Federal University of Pará, Belém, PA, Brazil.
Paulo Ricardo de Souza MeloPharmaceutical Sciences Postgraduate Program, Federal University of Pará, Belém, PA, Brazil.
Sandro PercarioBiotechnology and Biodiversity Postgraduate Program (BIONORTE), Federal University of Pará, Belém, PA, Brazil.
Fábio Alberto de MolfettaLaboratory of Molecular Modeling, Institute of Exact and Natural Sciences, Federal University of Pará, Belém, PA, Brazil.
Maria Fâni DolabelaBiotechnology and Biodiversity Postgraduate Program (BIONORTE), Federal University of Pará, Belém, PA, Brazil.
Universidade Federal do Pará · BRInstituto Evandro Chagas · BRDeoxi Biotecnologia (Brazil) · BRInstituto Federal de Educação, Ciência e Tecnologia do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antiamastigote activityisoeleutherinmedical plantnaftoquinonestrypanothione reductase

Identifiers

PMID38510811
PMCPMC10950963
OpenAlexW4392515504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.